Sanofi profit falls 13% in 2012
MOSCOW. Feb 7 (Interfax) - French pharmaceuticals company Sanofi-Aventis SA saw net profit fall 12.8% year-on-year in 2012 to 4.97 billion euros, the company said.
Profit per share also went down 12.8% to 3.76 euros. Gross profit was 24.86 billion euros, up 0.9%. Spending on R&D increased 2.3% to 4.92 billion euros.
Net sales climbed 4.7% to 34.95 billion euros. Sales in the pharmaceuticals segment increased 3.5% to 28.87 billion euros and sales of vaccines went up 12.3% to 3.9 billion euros. Emerging markets accounted for 11.14 billion euros worth of sales, up 9.9%. Sales in Eastern Europe, Russia and Turkey rose 2% to 2.72 billion euros.
Revenue from diabetes treatments surged 23.4% to 5.78 billion euros. Sales jumped 26.6% to 4.96 billion euros for Lantus, 1.2% to 2.07 billion for Plavix, 10.4% to 2.11 billion for Lovenox, 10.9% to 1.15 billion for Aprovel and 10.8% to 956 million euros for Eloxatin.
The company forecasts that revenue might fall 5% in 2013 and profit per share, not counting several expenses, will at best remain at the 2012 level and at worst fall 5%.
